Recorded fact · drug.trial_access

drug.trial_access for acalabrutinib

One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 351fa16e resolves to.

The record

Fact id	`351fa16e5964cfcf54f60d3a`
Entity	drug: acalabrutinib
Field	drug.trial_access
Source	clinicaltrials.gov
Read on	2026-11-07T06:34:32.466Z
Source version	clinicaltrials-api-2.0.5-data-2026-11-06T10:00:05
Method	api
Verification	machine_read
Licence	Terms and Conditions (last updated 2023-01-31) READ in full 2026-11-07: data free to all requesters; reuse allowed on conditions: attribute ClinicalTrials.gov, keep data current, display the date the registry processed the data, state any modifications; do not represent the data as other than a US Government database; no use of extracted email addresses for marketing; some records may carry third-party copyright (consult the submitter) and the data carry an international copyright outside the US. API rate guidance page UNREAD (JS page rendered no text 2026-11-07). AMBER because of the third-party copyright caveat on submitter text; counts and ids are safe, long free text is not reproduced. \| DISPLAY CONDITIONS (any page or delivery using this source): attribute ClinicalTrials.gov, show the registry processing date, state our modifications, never present as other than a US Government database, never use extracted emails for marketing.
Edition	2026-11, Merkle root `006ab9a329709cbe...`

This fact carries no verifying quote; its source is the dataset named above.

The value

{
 "ingredient": "ACALABRUTINIB",
 "recruitingInterventionalCount": 37,
 "notYetRecruitingCount": 4,
 "byPhase": {
  "PHASE2": 19,
  "PHASE1/PHASE2": 6,
  "PHASE3": 7,
  "PHASE4": 1,
  "PHASE1": 2,
  "NA": 1,
  "PHASE2/PHASE3": 1
 },
 "trials": [
  {
   "nctId": "NCT07582159",
   "briefTitle": "Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "City of Hope Medical Center",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-06",
   "startDate": "2026-12-19",
   "conditions": [
    "Chronic Lymphocytic Leukemia",
    "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
    "Small Lymphocytic Lymphoma"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07582159"
  },
  {
   "nctId": "NCT06054776",
   "briefTitle": "Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "City of Hope Medical Center",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-03",
   "startDate": "2024-12-02",
   "conditions": [
    "Mantle Cell Lymphoma"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06054776"
  },
  {
   "nctId": "NCT04404088",
   "briefTitle": "Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "M.D. Anderson Cancer Center",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-02",
   "startDate": "2020-07-16",
   "conditions": [
    "Ann Arbor Stage III Grade 1 Follicular Lymphoma",
    "Ann Arbor Stage III Grade 2 Follicular Lymphoma",
    "Ann Arbor Stage III Grade 3 Follicular Lymphoma"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT04404088"
  },
  {
   "nctId": "NCT05952024",
   "briefTitle": "Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "AstraZeneca",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-30",
   "startDate": "2024-07-16",
   "conditions": [
    "Diffuse Large B-Cell Lymphoma"
   ],
   "countries": [
    "United States",
    "Brazil",
    "Puerto Rico",
    "South Korea",
    "Taiwan"
   ],
   "url": "https://clinicaltrials.gov/study/NCT05952024"
  },
  {
   "nctId": "NCT06520098",
   "briefTitle": "A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "VA Office of Research and Development",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-30",
   "startDate": "2025-10-01",
   "conditions": [
    "Chronic Lymphocytic Leukemia",
    "Small Lymphocytic Lymphoma"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06520098"
  },
  {
   "nctId": "NCT06564038",
   "briefTitle": "A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies",
   "phase": [
    "PHASE1",
    "PHASE2"
   ],
   "leadSponsor": "AstraZeneca",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-28",
   "startDate": "2025-01-30",
   "conditions": [
    "Chronic Lymphocytic Leukaemia",
    "Small Lymphocytic Lymphoma",
    "Mantle-cell Lymphoma"
   ],
   "countries": [
    "United States",
    "Australia",
    "China",
    "Czechia",
    "Denmark",
    "France",
    "Germany",
    "Italy",
    "Japan",
    "South Korea"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06564038"
  },
  {
   "nctId": "NCT07029737",
   "briefTitle": "A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "AstraZeneca",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-27",
   "startDate": "2025-09-05",
   "conditions": [
    "Mantle-cell Lymphoma"
   ],
   "countries": [
    "Spain"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07029737"
  },
  {
   "nctId": "NCT04002947",
   "briefTitle": "Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "National Cancer Institute (NCI)",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-26",
   "startDate": "2019-08-05",
   "conditions": [
    "Non-Hodgkin's Lymphoma",
    "Diffuse Large B-Cell Lymphoma",
    "DLBCL"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT04002947"
  },
  {
   "nctId": "NCT03516617",
   "briefTitle": "Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "Mayo Clinic",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-26",
   "startDate": "2018-09-10",
   "conditions": [
    "Chronic Lymphocytic Leukemia",
    "Small Lymphocytic Lymphoma"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT03516617"
  },
  {
   "nctId": "NCT04941716",
   "briefTitle": "Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "Fred Hutchinson Cancer Center",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-23",
   "startDate": "2023-05-31",
   "conditions": [
    "Recurrent Chronic Lymphocytic Leukemia",
    "Recurrent
... (shortened here; the full value is in the JSON twin)

SHA-256 of the exact stored value: ecc125dbcdf9a2ca96f3154ed80e9a296406c9291c9f6b65cd9348d1c2b23813.

This fact as data (JSON) · Check an answer against its receipt · Licence

Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.